SUMMARY
# CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs AD with Concomitant NPH
## Background and Rationale
This innovative clinical study addresses a major diagnostic challenge in neurology by developing dynamic CSF biomarkers to differentiate normal pressure hydrocephalus (NPH) from Alzheimer's disease with concomitant NPH features. The clinical presentation of these conditions often overlaps significantly, leading to diagnostic uncertainty and suboptimal treatment decisions. Current sta
METHODOLOGY NOTES
**Phase 1: Patient Recruitment and Clinical Assessment (Months 1-8)**
Recruit 200 participants across three groups: 75 patients with idiopathic normal pressure hydrocephalus (iNPH), 75 patients with Alzheimer's disease and concomitant NPH features (AD+NPH), and 50 age-matched controls. Inclusion criteria include age >60 years, clinical symptoms of gait disturbance and cognitive impairment, and ventricular enlargement (Evans index >0.3). Exclude patients with secondary causes of hydrocephalus, severe medical comorbidities, or contraindications to lumbar puncture. Perform comprehensive neuropsychological testing using Montreal Cognitive Assessment (MoCA), Timed Up and Go test, and NPH grading scale. Obtain amyloid PET imaging using [18F]florbetapir to confirm amyloid status in suspected AD+NPH cases.
**Phase 2: CSF Dynamic Studies and Biomarker Analysis (Months 3-15)**
Conduct CSF tap tests with pre- and post-drainage clinical assessments at 1, 6, 24, and 72 hours. Remove 30-50 mL CSF